Category

News
While chimeric antigen receptor (CAR)-T cell therapy has demonstrated positive response rates in children with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), severe toxicities can also be associated with such treatment. So, a group of researchers issued guidelines to help ensure these patients experience optimal outcomes. “These guidelines are meant to be a truly...
Continue Reading
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands for T-cell. Currently both Novartis (NVS) and Gilead (NASDAQ:GILD) have CAR-T therapies approved by the FDA. Axicabtagene (Yescarta) is sold by Gilead and is approved for refractory diffuse large b...
Continue Reading
The human immune system is truly a wonder. It plays a critical role in our body’s defense to invading disease. Like a home security system, it is on alert 24/7/365. Through multiple mechanisms, it guards all our tissues, protects us from microbial foreign invaders, and removes cancer cells to keep us disease-free. For example, B...
Continue Reading
A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized treatments for myeloma patients. A research group in Singapore has used artificial intelligence (AI) to identify optimized combinatorial drug treatments for myeloma, a type of blood cancer. Their methods and findings are published in Science Translational Medicine....
Continue Reading
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer (NCT02414269). Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 checkpoint inhibition treatment. Preliminary results from the...
Continue Reading
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability and overcome patient’s ineffective immune surveillance. MRD analysis...
Continue Reading
Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, the game-changing cancer treatment approved by the FDA for 2 indications, and being studied for more. The request for an NCD was put forth by UnitedHealthcare, the nation’s largest insurer and...
Continue Reading
Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he’s ready for his experimental treatment. “How’s your night? Any issues?” asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid. Reid, 20, of Lucedale, Miss., has been fighting leukemia...
Continue Reading
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more: https://www.biopharma-reporter.com/Article/2018/08/15/US-FDA-approves-first-non-gene-edited-allogeneic-CAR-T-cell-candidate-for-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
Continue Reading
1 21 22 23 24 25 29

Floor 7, 90 The Terrace
Wellington Central
New Zealand